Solmaz Sahebjam
Elite in Brain Tumor

Dr. Solmaz Sahebjam

Oncology
Johns Hopkins Medicine
Sibley Memorial Hospital
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Elite in Brain Tumor
Johns Hopkins Medicine
Sibley Memorial Hospital
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Solmaz Sahebjam is a medical oncologist and an associate professor of oncology at Johns Hopkins University School of Medicine. Her expertise is in primary and metastatic brain tumors, breast cancer, and the development of new drugs for cancer. She earned her medical degree from Iran University of Medical Sciences, followed by a post-doctoral research fellowship at Shriners Hospital, McGill University in Montreal. Dr. Sahebjam completed residency training in internal medicine at Saint Vincent Hospital, followed by a fellowship in internal medicine at the University of Ottawa in Canada. She continued her training with a residency in medical oncology at McGill University in Canada followed by a fellowship in early-phase drug development, breast oncology, and neurooncology at Princess Margaret Hospital, University of Toronto in Canada. Dr. Sahebjam’s research is focused on the development of novel therapeutic regimens for the treatment of cancer including breast and central nervous system malignancies. Over the years, she has led and contributed to numerous clinical trials some of which have resulted in new treatment options for patients with cancer.

Dr. Sahebjam is rated as an Elite provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Glioma, Brain Tumor, Glioblastoma, Astrocytoma, and Awake Craniotomy.

Her clinical research consists of co-authoring 81 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 38 articles and participated in 7 clinical trials in the study of Brain Tumor.

Residency
McGill University School of Medicine, Medical Oncology, 2011
Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Toronto Health, Neuro-Oncology, 2013
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Azerbaijani
Farsi
French
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Sibley Memorial Hospital
Building B, Washington, DC 20016
Call: 202-660-6500
Other Locations
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: OBT076
Study Phase: Phase 1
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Phase IB Study of Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Radiation, Drug
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Vorinostat, Temozolomide
Study Phase: Phase 1
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Radiation, Drug
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 1
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Topotecan
Study Phase: Early Phase 1
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: IRX-2, Nivolumab
Study Phase: Phase 1
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Bevacizumab, Ipilimumab
Study Phase: Phase 1
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Trametinib, Sorafenib
Study Phase: Phase 1
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer
Enrollment Status: Terminated
Publish Date: February 04, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

81 Total Publications

Imaging progression after radiotherapy for IDH mutant low-grade glioma: Sometimes it is best to stay calm and stay the course.
Imaging progression after radiotherapy for IDH mutant low-grade glioma: Sometimes it is best to stay calm and stay the course.
Journal: Neuro-oncology practice
Published: August 15, 2025
View All 81 Publications
Similar Doctors
Matthias Holdhoff
Elite in Brain Tumor
Dr. Matthias Holdhoff
Oncology
Elite in Brain Tumor
Dr. Matthias Holdhoff
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (36.2 miles away)
410-955-8964
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Elite in Brain Tumor
Dr. Stuart Grossman
Oncology
Elite in Brain Tumor
Dr. Stuart Grossman
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (36.2 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

David O. Kamson
Elite in Brain Tumor
Dr. David O. Kamson
Oncology
Elite in Brain Tumor
Dr. David O. Kamson
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (36.2 miles away)
410-955-8964
Languages Spoken:
English, Hungarian
See accepted insurances
Offers Telehealth

David Kamson is an Oncologist in Baltimore, Maryland. Dr. Kamson is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Brain Tumor, Glioblastoma, Gliosarcoma, Metastatic Brain Tumor, and Hormone Replacement Therapy (HRT).

VIEW MORE BRAIN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sahebjam's expertise for a condition
ConditionClose
  • Elite
  • Astrocytoma
    Dr. Sahebjam is
    Elite
    . Learn about Astrocytoma.
    See more Astrocytoma experts
  • Brain Tumor
    Dr. Sahebjam is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Glioblastoma
    Dr. Sahebjam is
    Elite
    . Learn about Glioblastoma.
    See more Glioblastoma experts
  • Glioma
    Dr. Sahebjam is
    Elite
    . Learn about Glioma.
    See more Glioma experts
  • Metastatic Brain Tumor
    Dr. Sahebjam is
    Elite
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Distinguished
  • Atypical Teratoid Rhabdoid Tumor (ATRT)
    Dr. Sahebjam is
    Distinguished
    . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
    See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
  • Embryonal Tumor with Multilayered Rosettes
    Dr. Sahebjam is
    Distinguished
    . Learn about Embryonal Tumor with Multilayered Rosettes.
    See more Embryonal Tumor with Multilayered Rosettes experts
  • Ependymoma
    Dr. Sahebjam is
    Distinguished
    . Learn about Ependymoma.
    See more Ependymoma experts
  • Gliomatosis Cerebri
    Dr. Sahebjam is
    Distinguished
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Hemangiopericytoma
    Dr. Sahebjam is
    Distinguished
    . Learn about Hemangiopericytoma.
    See more Hemangiopericytoma experts
  • Neuroepithelioma
    Dr. Sahebjam is
    Distinguished
    . Learn about Neuroepithelioma.
    See more Neuroepithelioma experts
View All 8 Distinguished Conditions
  • Advanced
  • Breast Cancer
    Dr. Sahebjam is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Medulloblastoma
    Dr. Sahebjam is
    Advanced
    . Learn about Medulloblastoma.
    See more Medulloblastoma experts
  • Posterior Fossa Tumor
    Dr. Sahebjam is
    Advanced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Sahebjam is
    Advanced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
  • Experienced
  • Awake Craniotomy
    Dr. Sahebjam is
    Experienced
    . Learn about Awake Craniotomy.
    See more Awake Craniotomy experts
  • Brain Stem Cancer
    Dr. Sahebjam is
    Experienced
    . Learn about Brain Stem Cancer.
    See more Brain Stem Cancer experts
  • Dysembryoplastic Neuroepithelial Tumors (DNET)
    Dr. Sahebjam is
    Experienced
    . Learn about Dysembryoplastic Neuroepithelial Tumors (DNET).
    See more Dysembryoplastic Neuroepithelial Tumors (DNET) experts
  • Epithelial-Myoepithelial Carcinoma
    Dr. Sahebjam is
    Experienced
    . Learn about Epithelial-Myoepithelial Carcinoma.
    See more Epithelial-Myoepithelial Carcinoma experts
  • Ganglioglioma
    Dr. Sahebjam is
    Experienced
    . Learn about Ganglioglioma.
    See more Ganglioglioma experts
  • Hypothalamic Hamartomas
    Dr. Sahebjam is
    Experienced
    . Learn about Hypothalamic Hamartomas.
    See more Hypothalamic Hamartomas experts
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.